APC/Cyanine7 anti-mouse CD62L Antibody

Pricing & Availability
Clone
MEL-14 (See other available formats)
Regulatory Status
RUO
Other Names
L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
MEL14_APCCy7_031010
C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) APC/Cyanine7 (red histogram) or rat IgG2a FITC isotype control (blue histogram).
  • MEL14_APCCy7_031010
    C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) APC/Cyanine7 (red histogram) or rat IgG2a FITC isotype control (blue histogram).
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
104427 25 µg 94 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104428 100 µg 248 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Additional Product Notes
BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  2. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  3. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  4. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
  5. Orvain C, et al. 2022. Arthritis Res Ther. 24:13. PubMed
  6. Koutník J, et al. 2022. Front Immunol. 13:1049033. PubMed
  7. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  8. Kurosawa M, et al. 2021. Int J Mol Sci. 22:. PubMed
  9. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  10. Stewart I et al. 2018. Immunity. 49(3):477-489 . PubMed
  11. Lin R, et al. 2020. Sci Rep. 10:14397. PubMed
  12. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  13. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  14. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  15. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  16. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  17. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  18. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  19. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  20. Fumagalli V, et al. 2020. J Exp Med. :217. PubMed
  21. Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed
  22. Topham T 2010. J Immunol. 184:3841. PubMed
  23. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
  24. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  25. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  26. Ly A, et al. 2020. Cell Reports. 29(8):2257-2269.e6.. PubMed
  27. Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed
  28. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  29. Rengarajan S, et al. 2020. Cell Rep Med. :1. PubMed
  30. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  31. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  32. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  33. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  34. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  35. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  36. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  37. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  38. Tomala J, et al. 2020. Methods Mol Biol. 2111:101. PubMed
  39. Studniberg SI, et al. 2022. Mol Syst Biol. 18:e10824. PubMed
  40. Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed
  41. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  42. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  43. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  44. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  45. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  46. Frantz PN, et al. 2021. Nat Commun. 12:6277. PubMed
  47. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  48. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  49. Ryg-Cornejo V, et al. 2016. Cell Rep. 14:68-81. PubMed
  50. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  51. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
RRID
AB_830798 (BioLegend Cat. No. 104427)
AB_830799 (BioLegend Cat. No. 104428)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
UniProt
View information about CD62L on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account